(P063) Can Some High-Risk Prostate Cancer Patients Be Treated With a Shorter Course of Androgen Deprivation Therapy (ADT)?

Publication
Article
OncologyOncology Vol 29 No 4_Suppl_1
Volume 29
Issue 4_Suppl_1

This study suggests that certain patients with high-risk prostate cancer may be effectively treated with a shorter course of hormone ablation therapy. Longer follow-up and more patients will be needed to verify the efficacy of a shorter course of hormone ablation therapy in this patient population.

Seungtaek Choi, MD, Quynh-Nhu Nguyen, MD, Sean E. McGuire, MD, PhD, Karen E. Hoffman, MD, MPH, Thomas J. Pugh, MD, Steven J. Frank, MD, Usama Mahmood, MD, Deborah A. Kuban, MD, Andrew K. Lee, MD, MPH; UT MD Anderson Cancer Center

PURPOSE: To determine the efficacy of a shorter course of androgen deprivation therapy (ADT) in patients with high-risk prostate cancer.

MATERIALS AND METHODS: Charts of 472 high-risk prostate cancer (stage ≥ T3a, Gleason ≥ 8, or prostate-specific antigen [PSA] > 20.0 ng/mL) treated between 2000 and 2012 were reviewed. Eighty patients who were treated with a shorter course of ADT (≤ 12 mo of a gonadotropin-releasing hormone [GnRH] agonist) were analyzed for this study. All patients were treated with image-guided radiation therapy with either intensity-modulated radiation therapy or proton therapy. The median total dose given was 76 Gy in 2-Gy fractions (range: 74–86.4 Gy in 1.8–2.0-Gy fractions). Patients were followed with PSA measurements taken at 3–6-month intervals after the radiation therapy. Biochemical failure was defined as nadir + 2 as per the Phoenix definition. Biochemical relapse–free survival and prostate cancer–specific survival were calculated using the Kaplan-Meier method.

RESULTS: Median age was 73 years (range: 52–89 yr). The ADT duration was ≤ 6 months in 18 patients (22.5%) and 9–12 months in 62 patients (77.5%). The distribution of T stage was as follows: 1 patient with TX (1.3%), 31 with T1c (38.8%), 23 with T2a (27.5%), 10 with T2b (12.5%), 5 with T2c (6.2%), 6 with T3a (7.5%), and 5 with T3b (6.2%). The distribution of Gleason scores was as follows: 6 patients (7.5%) with Gleason 7 (3 + 4), 9 (11.2%) with Gleason 7 (4 + 3), 53 (66.2%) with Gleason 8 (4 + 4), 11 (13.8%) with Gleason 9 (4 + 5), and 1 (1.3%) with Gleason 9 (5 + 4). Four patients had PSA < 4 ng/mL (5.0%), 48 patients had PSA 4.1–10 ng/mL (60.0%), 19 patients had PSA 10.1–20 ng/mL (23.8%), and 9 patients had PSA > 20 ng/mL (11.2%). The majority of patients had disease at the lower end of the high-risk spectrum (stage ≤ T2 [85.0%], Gleason ≤ 8 [84.9%], and PSA ≤ 20 ng/mL [88.8%]). Median follow-up was 38 months (range: 3–158 mo). Actuarial 4-year biochemical relapse–free survival was 91%. There were four biochemical failures seen, with a median time to failure of 33.5 months (range: 27–48 mo). There was no significant correlation between T stage, Gleason score, PSA, or duration of hormone ablation therapy and recurrence. Although there were 10 deaths in this patient population, none of the deaths was related to prostate cancer.

CONCLUSIONS: This study suggests that certain patients with high-risk prostate cancer may be effectively treated with a shorter course of hormone ablation therapy. Longer follow-up and more patients will be needed to verify the efficacy of a shorter course of hormone ablation therapy in this patient population.

Proceedings of the 97th Annual Meeting of the American Radium Society- americanradiumsociety.org

Articles in this issue

(P005) Ultrasensitive PSA Identifies Patients With Organ-Confined Prostate Cancer Requiring Postop Radiotherapy
(P001) Disparities in the Local Management of Breast Cancer in the United States According to Health Insurance Status
(P002) Predictors of CNS Disease in Metastatic Melanoma: Desmoplastic Subtype Associated With Higher Risk
(P003) Identification of Somatic Mutations Using Fine Needle Aspiration: Correlation With Clinical Outcomes in Patients With Locally Advanced Pancreatic Cancer
(P004) A Retrospective Study to Assess Disparities in the Utilization of Intensity-Modulated Radiotherapy (IMRT) and Proton Therapy (PT) in the Treatment of Prostate Cancer (PCa)
(S001) Tumor Control and Toxicity Outcomes for Head and Neck Cancer Patients Re-Treated With Intensity-Modulated Radiation Therapy (IMRT)-A Fifteen-Year Experience
(S003) Weekly IGRT Volumetric Response Analysis as a Predictive Tool for Locoregional Control in Head and Neck Cancer Radiotherapy 
(S004) Combination of Radiotherapy and Cetuximab for Aggressive, High-Risk Cutaneous Squamous Cell Cancer of the Head and Neck: A Propensity Score Analysis
(S005) Radiotherapy for Carcinoma of the Hypopharynx Over Five Decades: Experience at a Single Institution
(S002) Prognostic Value of Intraradiation Treatment FDG-PET Parameters in Locally Advanced Oropharyngeal Cancer
(P006) The Role of Sequential Imaging in Cervical Cancer Management
(P008) Pretreatment FDG Uptake of Nontarget Lung Tissue Correlates With Symptomatic Pneumonitis Following Stereotactic Ablative Radiotherapy (SABR)
(P009) Monte Carlo Dosimetry Evaluation of Lung Stereotactic Body Radiosurgery
(P010) Stereotactic Body Radiotherapy for Treatment of Adrenal Gland Metastasis: Toxicity, Outcomes, and Patterns of Failure
(P011) Stereotactic Radiosurgery and BRAF Inhibitor Therapy for Melanoma Brain Metastases Is Associated With Increased Risk for Radiation Necrosis
Related Videos
Collaboration among nurses, social workers, and others may help in safely administering outpatient bispecific T-cell engager therapy to patients.
Nurses should be educated on cranial nerve impairment that may affect those with multiple myeloma who receive cilta-cel, says Leslie Bennett, MSN, RN.
Treatment with cilta-cel may give patients with multiple myeloma “more time,” according to Ishmael Applewhite, BSN, RN-BC, OCN.
Nurses may need to help patients with multiple myeloma adjust to walking differently in the event of peripheral neuropathy following cilta-cel.
Tailoring neoadjuvant therapy regimens for patients with mismatch repair deficient gastroesophageal cancer represents a future step in terms of research.
Not much is currently known about the factors that may predict pathologic responses to neoadjuvant immunotherapy in this population, says Adrienne Bruce Shannon, MD.
Data highlight that patients who are in Black and poor majority areas are less likely to receive liver ablation or colorectal liver metastasis in surgical cancer care.
Findings highlight how systemic issues may impact disparities in outcomes following surgery for patients with cancer, according to Muhammad Talha Waheed, MD.
Pegulicianine-guided breast cancer surgery may allow practices to de-escalate subsequent radiotherapy, says Barbara Smith, MD, PhD.
Adrienne Bruce Shannon, MD, discussed ways to improve treatment and surgical outcomes for patients with dMMR gastroesophageal cancer.
Related Content